Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report) shares gapped up before the market opened on Monday . The stock had previously closed at $10.75, but opened at $11.48. Pharming Group shares last traded at $11.39, with a volume of 3,990 shares trading hands.
Analyst Upgrades and Downgrades
Several research analysts recently commented on PHAR shares. HC Wainwright reaffirmed a "buy" rating and issued a $37.00 price target on shares of Pharming Group in a research note on Thursday, March 20th. Oppenheimer increased their price target on Pharming Group from $30.00 to $39.00 and gave the stock an "outperform" rating in a research report on Friday, March 14th.
View Our Latest Stock Analysis on PHAR
Pharming Group Price Performance
The company has a debt-to-equity ratio of 0.39, a current ratio of 2.76 and a quick ratio of 2.00. The firm's 50-day moving average price is $9.82 and its two-hundred day moving average price is $9.23.
Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.22) EPS for the quarter, topping analysts' consensus estimates of ($0.25) by $0.03. The company had revenue of $79.09 million during the quarter, compared to the consensus estimate of $67.74 million. Pharming Group had a negative net margin of 4.14% and a negative return on equity of 6.01%. As a group, equities analysts expect that Pharming Group N.V. Sponsored ADR will post -0.2 EPS for the current year.
About Pharming Group
(
Get Free Report)
Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.
See Also
Before you consider Pharming Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pharming Group wasn't on the list.
While Pharming Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
